Expression and Subcellular Localization of the Cyclin-Dependent Kinase Inhibitor p27 Kip1 in Epithelial Ovarian Cancer

By Hurteau J.A.   Allison B.M.   Brutkiewicz S.A.   Goebl M.G.   Heilman D.K.   Bigsby R.M.   Harrington M.A.  

Gynecologic Oncology, Vol. 83, Iss. 2, 2001-11 ,pp. : 292-298

Elsevier

Access to resources Recommend Favorite

Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 (Kip1) in estrogen-related endometrial adenocarcinomas

By Torricelli Michela   Sanseverino Francesca  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 19-20

Informa Healthcare

Access to resources Recommend Favorite

Cyclin-dependent kinase inhibitor p27 as a prognostic biomarker and potential cancer therapeutic target

By Hershko Dan D  

Future Oncology, Vol. 6, Iss. 12, 2010-12 ,pp. : 1837-1847

Future Medicine

Access to resources Recommend Favorite

Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27 KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines

By Shintani S.   Li C.   Mihara M.   Yano J.   Terakado N.   Nakashiro K.-i.   Hamakawa H.  

Oral Oncology, Vol. 40, Iss. 1, 2004-01 ,pp. : 43-51

Elsevier

Access to resources Recommend Favorite

Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma

By          

Molecular Medicine Reports, Vol. 13, Iss. 1, 2016-01 ,pp. : 713-719

Spandidos Publications

Access to resources Recommend Favorite